Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19)
暂无分享,去创建一个
M. Vignetti | G. Gaidano | G. Torelli | V. Rizzoli | A. Venditti | S. Suciu | S. Amadori | R. Stasi | G. Alimena | P. Muus | D. Selleslag | F. Lauria | L. Baila | T. de Witte | E. Borlenghi | E. Cacciola | D. Magro | T. D. de Witte
[1] E. Estey,et al. Treatment of acute myeloid leukemia , 2009, Haematologica.
[2] A. Venditti,et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. , 2008, Cancer treatment reviews.
[3] N. Freemantle,et al. Composite and surrogate outcomes in randomised controlled trials , 2007, BMJ : British Medical Journal.
[4] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[5] E. Estey. Advances in the management of AML in the elderly. , 2007, Clinical advances in hematology & oncology : H&O.
[6] R. Bouabdallah,et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.
[7] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[8] F. Mandelli,et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[10] E. Estey,et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.
[11] Nick Freemantle,et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? , 2003, JAMA.
[12] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[13] C. Earle,et al. The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.
[14] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[16] I. Bernstein,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .
[17] D. Scheinberg,et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.